Nasdaq:US$15.05 (-0.05) | HKEX:HK$23.55 (-0.20) | AIM:£2.22 (-0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)